A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Trial details
- Registry ID
- NCT06680258
- Drugs studied
- Atezolizumab, Bevacizumab, TPST-1120
TrialRedline tracks 1 clinical trial sponsored by Tempest Therapeutics: 1 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258 | Atezolizumab, Bevacizumab, TPST-1120 | Not yet recruiting | 2028-12Estimated |
Names as written in the registry records.